DexCom, Inc. (NASDAQ:DXCM) Stock Position Decreased by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 0.8% in the first quarter, Holdings Channel.com reports. The institutional investor owned 15,376 shares of the medical device company’s stock after selling 123 shares during the quarter. Ameritas Investment Partners Inc.’s holdings in DexCom were worth $2,133,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Capital World Investors boosted its stake in DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the period. Norges Bank acquired a new position in DexCom during the 4th quarter valued at about $540,178,000. Artisan Partners Limited Partnership boosted its stake in DexCom by 164.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the period. Capital Research Global Investors boosted its stake in DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new position in DexCom during the 4th quarter valued at about $231,773,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 0.4 %

Shares of DXCM stock traded up $0.48 during trading hours on Tuesday, reaching $112.13. 2,369,733 shares of the stock traded hands, compared to its average volume of 2,856,004. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business has a fifty day moving average price of $117.74 and a 200 day moving average price of $124.57. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $44.59 billion, a PE ratio of 72.03, a PEG ratio of 2.73 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. On average, equities research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research analyst reports. Morgan Stanley reduced their price target on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Stifel Nicolaus reduced their price target on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a research note on Friday, July 12th. Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Finally, Redburn Atlantic initiated coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $139.33.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the transaction, the executive vice president now owns 67,560 shares in the company, valued at approximately $8,055,854.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other DexCom news, CFO Jereme M. Sylvain sold 745 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the sale, the chief financial officer now directly owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $119.24, for a total transaction of $77,744.48. Following the sale, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,112 shares of company stock worth $480,861. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.